EXTENDED REPORT

Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial

J S Smolen,1 P Emery,2,3 G F Ferraccioli,4 W Samborski,5 F Berenbaum,6 O R Davies,7 W Koeste,8 O Purcaru,7 B Bennett,9 H Burkhardt10

ABSTRACT

Objectives This 52-week, randomised, double-blind phase IIIb study assessed efficacy and safety of certolizumab pegol (CZP) as add-on therapy to non-biologic disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients with low to moderate disease activity, and stopping therapy in patients in sustained remission.

Methods Patients were randomised 1:1 to CZP (400 mg at weeks 0, 2 and 4, then 200 mg every 2 weeks) or placebo (every 2 weeks) plus current non-biologic DMARDs. At week 24, patients who achieved the primary endpoint of Clinical Disease Activity Index (CDAI) remission at both weeks 20 and 24 stopped study treatment and continued in the study until week 52.

Results Of 194 patients (CZP=96; placebo=98), >90% had moderate disease activity at baseline. Significantly more CZP patients met the primary endpoint than placebo patients (week 20 and 24 CDAI remission rates: 18.8% vs 6.1%; p≤0.05). At week 24, 63.0% vs 29.7% of CZP versus placebo patients (p<0.001) achieved LDA. Disease activity score (ESR) based on 28-joint count and Simplified Disease Activity Index remission rates were also significantly higher with CZP versus placebo (19.8% vs 3.1%; p≤0.01 and 14.6% vs 4.1%; p≤0.05). CZP patients reported improvements in physical function versus placebo (mean Health Assessment Questionnaire-Disability-Index change from baseline: CZP, −0.25 vs placebo, −0.03; p≤0.01). During the period following withdrawal of CZP or placebo, only 3/17 prior CZP patients and 2/6 prior placebo patients maintained CDAI remission until week 52, but CZP reinitiation allowed renewed improvement. Adverse and serious adverse event rates were comparable between CZP and placebo groups.

Conclusions Addition of CZP to non-biologic DMARDs is an effective treatment in RA patients with predominantly moderate disease activity, allowing low-disease activity or remission to be reached in a majority of the patients. However, the data suggest that CZP cannot be withdrawn in patients achieving remission.

Trial registration number NCT00674362.

INTRODUCTION

Non-biologic disease-modifying antirheumatic drugs (DMARDs), including methotrexate (MTX), are standard therapy for rheumatoid arthritis (RA). While some patients have only a minimal response, continuing to show high-disease activity (HDA), and others attain remission, the majority achieve significant improvement but continue to have low to moderate disease activity (MDA).1–4 MDA is associated with a significant burden for patients and society regarding quality of life, productivity, comorbidities and costs when compared with remission.5–8 Furthermore, patients with MDA are likely to experience joint damage progression and loss of function with conventional DMARD therapy.2,3,8 For these reasons, the ‘Treat-to-Target’ paradigm, together with the European League Against Rheumatism (EULAR) recommendations for RA management, advocates clinical remission as the main target for RA patients.10–11 Recently, the definition of remission in RA has now been updated by ACR and EULAR, using Boolean- and index-based criteria; the latter employ the remission definitions by the simplified and clinical disease activity indices (Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI)).

Few randomised clinical trials have specifically investigated RA treatments in patients with low disease activity (LDA)/MDA, although data from post-hoc analyses, open-label studies and registries suggest that anti-TNFs are efficacious.12–14 Furthermore, there is little information regarding treatment adjustment once stringent remission is attained. Current EULAR recommendations state that once patients are in sustained remission, biologic therapies can be slowly reduced.11 Potential benefits of drug withdrawal include reduced healthcare costs, safety and convenience.

Certolizumab pegol (CZP) is a PEGylated Fab’ anti-TNF demonstrated to be efficacious and well tolerated in phase III clinical trials in RA patients with MDA/severe disease activity.13–22 However, in these studies, the vast majority of patients had HDA (mean disease activity score (disease activity score (ESR) based on 28-joint count (DAS28) values 6.4 to 7.0).15 17 22 Here, we present results from the CERTAIN (CERTolizumab pegol in the treatment of RA: remission INduction and maintenance in patients with LDA) study, NCT00674362, which evaluated efficacy and safety of CZP as add-on therapy to current non-biologic DMARDs in patients with LDA/MDA. We also investigated whether CZP can be withdrawn when patients achieve remission and, if lost, whether remission/LDA could be regained upon CZP reinitiation.

METHODS

Patients

Eligible patients (≥18 years of age) had a diagnosis of RA (6 months–10 years), LDA/MDA at
screening and baseline (defined by CDAI >6 and ≤16, ≥2 tender joints (28-joint count, TJc), ≥2 swollen joints (28-joint count, SJc) and either erythrocyte sedimentation rate (Westergren-ESR) ≥28 mm/h or C-reactive protein (CRP) >10 mg/L). Patients must have received mono or combination DMARD therapy (MTX, leflunomide, sulfasalazine and/or hydroxychloroquine) for ≥6 months (dose stable ≥2 months) prior to baseline, with corticosteroid dose stable >1 month (for exclusion criteria, see online supplementary material).

**Study design**
CERTAIN was a randomised, double-blind, placebo-controlled 52-week (24-week treatment and 28-week follow-up period) phase IIIb study (figure 1A) conducted between June 2008 and December 2010. All patients, recruited from centres in Austria, France, Germany, Italy and Poland, provided written consent. The study protocol was approved by Ethics Committees at each centre and performed according to Declaration of Helsinki.

Patients were randomised in a 1:1 ratio to CZP or placebo. CZP patients received subcutaneous 400 mg CZP at weeks 0, 2 and 4, followed by 200 mg CZP every 2 weeks (Q2W) thereafter, controls receiving identical injections of 0.9% saline Q2W administered by unblinded site personnel. Randomisation was performed centrally using an interactive voice-response system. All patients continued their conventional DMARDs throughout.

At week 24, patients were divided depending on remission status: non-remitters (patients not achieving CDAI remission (CDAI≤2.8) at both weeks 20 and 24) were discontinued and given the opportunity to receive CZP in an open-label extension study (NCT00843778); remitters (patients in CDAI remission at weeks 20 and 24) stopped randomised treatment (CZP or placebo), stayed in the study until week 52 continuing their concomitant therapies blinded to original treatment. Remitters who flared (CDAI≥11 at 2 visits, 4 weeks apart) between weeks 24 and 50 were retreated with the same dosing regimen of CZP as used originally up to and including week 50, before entering the open-label extension. To maintain blinding of the first study period, prior placebo-treated patients who achieved remission also received CZP if they flared.

**Efficacy and safety evaluations**
Efficacy evaluations were performed every 4 weeks from weeks 0 to 52 (for exceptions, see online supplementary material). Adverse events (AEs) were assessed Q2W. Primary efficacy endpoint was the proportion of patients in stable CDAI remission (CDAI≤2.8) at both weeks 20 and 24.

Secondary efficacy endpoints included the proportion of patients with DAS28 (ESR)<2.6 and ACR-EULAR index-based SDAI remission (SDAI≤3.3) at both weeks 20 and 24, ACR20, ACR50 and ACR70 responders at week 24, and change from baseline in Health Assessment Questionnaire-Disability-Index (HAQ-DI), Patient’s Assessment of Arthritis Pain (100 mm visual analogue scale (VAS)), fatigue (11-point scale), Patient’s Global Assessment of Disease Activity (PtGA; VAS), SF-36 (Physical Component Summary (PCS), Mental Component Summary (MCS)) and time from stopping treatment to loss of remission (CDAI≥2.8) at 2 consecutive visits. SDAI and DAS28 (ESR) loss of remission (SDAI>3.3 and DAS28 (ESR)>2.6 at two consecutive visits) were similarly assessed. Exploratory objectives included CDAI, SDAI and DAS28 (ESR) over the 24-week treatment period. ACR-EULAR Boolean-based remission criteria using four variables (SJc and TJc≤1, CRP≤1 mg/dL and PtGA≤1) and three variables (SJc and TJc≤1 and PtGA≤1) were analysed posthoc. The impact of patients’ disease activity on work productivity was an exploratory objective and measured using the Work Productivity and Activity Impairment-RA (WPAI-RA) questionnaire (for details, see online supplementary material).

Safety analysis was performed up to week 52 plus 12-week safety follow-up (for details, see online supplementary material).

**Statistical analysis**
Sample size was calculated assuming 25% of patients in the placebo-treated group and at least 50% in the CZP-treated group would achieve remission (CDAI≤2.8) at both weeks 20 and 24. Planned sample size was 170 patients (85 for each treatment group) to achieve ≥90% power to show a statistically significant difference in proportions of patients in remission at both weeks 20 and 24. A two-sided Fisher’s exact test, significance level of 0.05 (α), was used.

Efficacy analyses were performed on the intent to treat (ITT) population (all randomised patients). The proportion of patients in CDAI/SDAI/DAS28 (ESR) remission and ACR responder rates were analysed using logistic regression models with treatment and geographic region as factors, from which ORs were estimated and presented with confidence intervals (CIs) and corresponding p values. Missing data were imputed by non-responder imputation (NRI) for CDAI, DAS28 (ESR) and SDAI remission rates, ACR responder rates and ACR-EULAR Boolean remission. Patients who withdrew for any reason or received rescue medication were considered non-responders from that time point onwards. All continuous data were analysed on the ITT population using analysis of covariance (ANCOVA) models with treatment and geographic region as factors and baseline value as covariate using last observation carried forward (LOCF) imputation. Safety analyses included all patients receiving study medication (CZP or placebo).

**RESULTS**
**Patients**
In total, 194 patients were randomised to placebo (n=98) or CZP (n=96); 80 (81.6%) and 84 (87.5%) patients, respectively, completed 24 weeks of treatment (figure 1B). Baseline characteristics were similar between groups (table 1), with >90% in MDA (CDAI>10). Two CZP-randomised patients had HDA (CDAI>22) at baseline, but were nevertheless included in the ITT population. In line with inclusion criteria, patients had low joint counts at baseline (mean TJc: 3.8; mean SJc: 3.3). Despite MDA, functional impairment was high (mean HAQ-DI: 1.1). Impairments in overall work and daily activities and thus economic burden were also substantial (see online supplementary figure S2).

**Clinical efficacy**
**Double-blind period: up to week 24**
Significantly more CZP-treated than placebo-treated patients reached the primary endpoint, CDAI remission at both weeks 20 and 24 (18.8% vs 6.1%; p≤0.05) (figure 2A), fewer than expected. Further, significantly more CZP than placebo patients had DAS28 (ESR) or SDAI remission at both weeks 20 and 24 (figure 2A).

Mean CDAI and SDAI scores in CZP-treated patients improved from baseline by week 4, while worsening on placebo treatment (figure 2B, see online supplementary figure S1). Mean change from baseline DAS28 (ESR) also improved on CZP remaining stable on placebo (see online supplementary figure S1). Over twice as many CZP-treated versus placebo-treated patients achieved LDA/remission at week 24 (63.0% vs 29.7%, 42.4% vs 16.5%) on December 29, 2023 by guest. Protected by copyright. http://ard.bmj.com/ Ann Rheum Dis: first published as 10.1136/annrheumdis-2013-204632 on 15 January 2014. Downloaded from http://ard.bmj.com/
Clinical and epidemiological research

(A) Study design and (B) CONSORT diagram showing patient flow.

and 65.2% vs 31.9% for CDAI, DAS28 and SDAI, respectively, all p<0.001 (figure 2C, see online supplementary figure S1), which was already observable at week 12. Furthermore, at week 24, more patients on placebo than CZP had HDA (figure 2C).

ACR-EULAR Boolean remission was achieved at week 24 by over twice as many CZP-treated than placebo-treated patients (Boolean 4: CZP=10.4%, placebo=5.1%; Boolean 3: CZP=14.6%, placebo=5.1%). ACR20, ACR50 and ACR70 response rates were higher at week 24 in the CZP group than the placebo group (ACR20, 36.5% vs 15.3%, OR 3.26 (95% CI 1.59 to 6.65); p≤0.001; ACR50, 20.8% vs 7.1%, OR 3.58 (95% CI 1.34 to 9.54); p≤0.05; ACR70, 9.4% vs 3.1%, OR 3.08 (95% CI 0.77 to 12.25); not significant although numerically threefold higher).

CZP-treated patients reported significant improvements in patient-reported outcomes compared with placebo (see online supplementary table S1 and figure 3A). Marked improvements in physical function were observed from week 4 onwards in CZP-treated compared with placebo-treated patients (figure 3A). Improvements were also seen in pain and fatigue assessments (figure 3B and C). Furthermore, patients who received CZP reported significant improvements at week 24 in both SF-36 PCS and MCS compared with those receiving placebo. Mean changes from baseline were PCS 6.0 vs 1.7, p≤0.01; MCS 4.0 vs 0.5, p≤0.05 (observed data, see online supplementary table S1).

At baseline, 32.6% patients were employed overall (35.9% in the CZP group and 29.3% in the placebo group). Over 24 weeks, CZP-treated patients reported on average greater reductions in absenteeism, presenteeism, overall work impairment and daily activity impairment compared with placebo-treated patients (see online supplementary figure S2). The percentage of work time missed due to RA (absenteeism) decreased on average from 11.0% at baseline to 3.3% at week 24 in the CZP group, whereas in the placebo group the impairment increased by week 24 (on average from 1.5% at baseline to 5.6% at week 24). The percentage of impairment while working due to RA (presenteeism) decreased on average from 35.3% at baseline to 23.6% at week 24 in the CZP group but did not change in the placebo group (37.7% at baseline compared with 38.5% at week 24) (see online supplementary figure S2).

Open-label follow-up period: up to week 52

Patients in sustained remission stopped CZP or placebo treatment at week 24, while maintaining their established DMARD regimens, blinded to initial treatment allocation. In total, 6 placebo-treated and 17 CZP-treated patients entered the follow-up period and were eligible for inclusion in the analysis. Of subjects completing 52 weeks of treatment, CDAI remission was maintained in 3/17 prior CZP-treated and 2/6 placebo-treated patients. At week 52, 7/17 prior CZP and 2/6 prior placebo patients had CDAI LDA/remission.

Ten of seventeen patients in the prior CZP group flared to MDA or HDA, and all achieved remission or LDA when retreated with CZP. Four patients in the prior placebo group flared; CZP treatment resulted in two patients achieving remission, one LDA and one MDA. Median time to loss of CDAI remission (in all patients) was 42.5 days (see online supplementary figure S3).
Figure 2  (A) Clinical Disease Activity Index (CDAI), Disease activity score (ESR) based on 28-joint count and Simplified Disease Activity Index remission at both Weeks 20 and 24 (intent to treat (ITT) population, non-responder imputation); (B) mean CDAI scores up to week 24 (ITT population, last observation carried forward); (C) CDAI disease state at baseline, week 12 and week 24 (ITT population, LOCF).

*By logistic regression with factors for treatment and geographic region/country

Figure 3  Improvements in (A) physical function (Health Assessment Questionnaire-Disability-Index), (B) pain (visual analogue scale) and (C) Fatigue Assessment Scale (FAS) over 24 weeks (ITT population, last observation carried forward).

MCID: Minimal Clinical Important Difference, defined as 0.22 for HAQ-DI; **p<0.01 (CZP – PBO LS mean difference in change from Baseline); ***p<0.001(CZP – PBO LS mean difference in change from Baseline).
Safety
AEs occurred in 68.8% and 67.3% of patients in the CZP and placebo groups, respectively, during the 24-week double-blind period (table 2; see online supplementary material). The most frequently reported AEs with CZP during the 24-week double-blind period were infections and infestations (36.5%), gastrointestinal disorders (19.8%), and musculoskeletal and connective tissue disorders (15.6%), with rates comparable in placebo-treated patients (37.8%, 13.3% and 19.4%, respectively). Incidence of SAEs was 5.2% for the CZP group (one event each of irritable bowel syndrome, otitis media, haemophilus sepsis, polyarthritis, intervertebral disc protrusion and RA) and 7.1% for the placebo group (one event each of pneumonia, tendon rupture, joint effusion, cerebrovascular accident and RA) and 7.1% for the placebo group (one event each of pneumonia, tendon rupture, joint effusion, cerebrovascular accident and RA) and 7.1% for the placebo group (one event each of pneumonia, tendon rupture, joint effusion, cerebrovascular accident and RA).

Table 2 Treatment-emergent adverse events in the safety population during the double-blind period

<table>
<thead>
<tr>
<th>Preferred term</th>
<th>Placebo (n=98)</th>
<th>CZP (n=96)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any AE, n (%)</td>
<td>66 (67.3%)</td>
<td>66 (68.8%)</td>
</tr>
<tr>
<td>Drug related, n (%)</td>
<td>26 (26.5%)</td>
<td>29 (30.2%)</td>
</tr>
<tr>
<td>Infections and infestations</td>
<td>37 (37.8%)</td>
<td>35 (36.5%)</td>
</tr>
<tr>
<td>Serious AEs, n (%)</td>
<td>7 (7.1%)</td>
<td>5 (5.2%)</td>
</tr>
<tr>
<td>Serious infections, n (%)</td>
<td>1 (1.0%)</td>
<td>2 (2.1%)</td>
</tr>
<tr>
<td>Malignancies</td>
<td>2 (2.0%)</td>
<td>0</td>
</tr>
<tr>
<td>AE leading to death, n (%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>AE leading to withdrawal*</td>
<td>6 (6.1%)</td>
<td>6 (6.3%)</td>
</tr>
</tbody>
</table>

Most common AE†
System order class
Preferred term
Infections and infestations | 37 (37.8%) | 35 (36.5%) |
Bronchitis | 5 (5.1%) | 3 (3.1%) |
Gastroenteritis | 3 (3.1%) | 1 (1.0%) |
Herpes simplex | 1 (1.0%) | 3 (3.1%) |
Influenza | 2 (2.0%) | 3 (3.1%) |
Nasopharyngitis | 11 (11.2%) | 10 (10.4%) |
Rhinitis | 2 (2.0%) | 3 (3.1%) |
Upper respiratory tract infection | 4 (4.1%) | 6 (6.3%) |
Urinary tract infection | 5 (5.1%) | 6 (6.3%) |
Gastrointestinal disorders | 13 (13.3%) | 19 (19.8%) |
Diarrhoea | 6 (6.1%) | 5 (5.2%) |
Abdominal pain | 2 (2.0%) | 4 (4.2%) |
Abdominal pain upper | 1 (1.0%) | 3 (3.1%) |
Nausea | 5 (5.1%) | 5 (5.2%) |
Nervous system disorders | 11 (11.2%) | 4 (4.2%) |
Headache | 5 (5.1%) | 0 |
Musculoskeletal and connective tissue disorders | 19 (19.4%) | 15 (15.6%) |
Rheumatoid arthritis | 5 (5.1%) | 3 (3.1%) |
Cardiac disorders | 1 (1.0%) | 6 (6.3%) |
Tachycardia | 0 | 3 (3.1%) |
Ear and labyrinth disorders | 3 (3.1%) | 1 (1.0%) |
Vertigo | 3 (3.1%) | 0 |
Vascular disorders | 4 (4.1%) | 3 (3.1%) |
Hypertension | 2 (2.0%) | 3 (3.1%) |

Results are shown as n (%) of patients.
*Temporary or permanent discontinuation of the drug.
†Treatment-emergent adverse events occurring in ≥3% (by preferred term) of the safety population in the specified period (in either certolizumab pegol or placebo group).
AE, Adverse event.

DISCUSSION
In the CERTAIN study of RA patients with mostly MDA, addition of CZP, compared with addition of placebo, to non-biologic DMARDs led to significantly higher rates of sustained remission or LDA as assessed by CDAI (almost two-thirds of patients) and other scores. In CERTAIN, the CDAI remission rates at weeks 20 and 24 (the primary endpoint) were similar to SDAI/CDAI remission rates at a comparable time point in the Prospective, Randomized Etanercept Study to Evaluate Reduced dose Etanercept + MTX v. full dose Etanercept + MTX v. MTX alone for efficacy and radiographic endpoints in a moderate RA population (PRESERVE) study, which indicates that in patients with long-standing disease duration achievement of stringent remission is difficult. Indeed, this finding supports the notion of the Treat-to-Target and EULAR recommendations that suggest use of LDA rather than remission as a treatment target in patients with established disease.10 11 Disease activity in patients receiving placebo (continuing non-biologic DMARDs) increased to week 24 by CDAI and SDAI, with over one-third of patients moving to an HDA state. This contrasts with decreases in disease activity in placebo-treated patients usually seen in clinical trials as a consequence of the ‘placebo effect’. Thus, in these patients, CZP addition not only led to more frequent good clinical states but also prevented disease worsening by inhibiting progression to HDA. This novel finding is aligned with observations that early RA patients with persistent MDA experience functional deterioration.2

Rapid and sustained improvements in CDAI, SDAI and DAS28(ESR), from the first time point at 4 weeks, were observed following CZP initiation, with the majority of response observed within 12 weeks.

Results were consistent across secondary endpoints, including SDAI and DAS28(ESR) remission, ACR20, ACR50 and ACR70 response rates, CDAI, SDAI and DAS28(ESR) values and patient-reported outcomes over the entire 24-week treatment period. The low number of baseline tender and swollen joints may have contributed to lower ACR responses than observed in other CZP studies; 79% of CZP-treated and 86% of placebo-treated patients had baseline TJC or SJC ≤3 and therefore could not achieve an ACR70 unless having 0 TJC and SJC by week 24.

CDAI and SDAI are considered the appropriate composite measures for definition of remission by ACR and EULAR.24] The primary endpoint of CERTAIN was CDAI remission at two consecutive time points at the end of the initial observation period, a stringent definition of remission. As CDAI does not include measures of acute phase reactants (APR), it is often more useful in routine clinical care.25 26 Unlike CDAI and SDAI, DAS28(ESR) is strongly influenced by absolute values and changes of APR levels,27 28 which are often profoundly affected by anticytokine agents.29

CERTAIN is a unique study, with the vast majority of included patients having MDA at baseline. Patients with LDA/MDA represent the largest RA subsets in routine clinical care,4 10 who generally have disease activity that is lower than the entry criteria for most clinical studies.31 This population accounts for a substantial economic burden, especially when considering impairments of physical function, work and daily activities.32 33 The economic burden of patients with low to moderate disease activity is supported in the CERTAIN study by the substantial impairment in work productivity observed at baseline. Furthermore, such patients continue to have progressive joint damage and functional impairment2 3 5 and the improvement in physical function and productivity, both in absenteeism, impairment in work-related productivity and impairment in...
daily activities, noted with CZP here, suggests substantial benefit in treating patients with this mostly moderate level of disease activity.

The Treat-to-Target concept, which has been used successfully in other therapeutic areas such as diabetes for many years, has become increasingly adopted in RA. Remission is recommended as the primary therapeutic aim, although LDA is an acceptable alternative particularly in patients with long-standing disease for whom remission may not be realistic; however, this latter recommendation was not based on primary evidence from controlled trials. Here we show that, in patients with established disease, stringent remission is difficult to achieve despite optimal therapy, even if patients have MDA at baseline, consistent with other studies including PRESERVE. The alternative target of LDA was attained in almost two-thirds of CZP patients at 6 months in the CERTAIN study. Interestingly, patients achieving remission had shorter disease duration and fewer prior DMARD therapies, indicating that remission is more difficult to achieve in patients with more refractory disease. Also, baseline HAQ-DI scores tended to be lower among remitters despite similar SDAI, CDAI and DAS28 values, in patients assigned to both CZP and placebo, consistent with the PRESERVE study. These may represent potential predictors for achievement of remission.

Current EULAR recommendations suggest considering withdrawal of biologic DMARDs in patients in stable remission. However, this study reveals that, upon stopping CZP therapy, most patients were unable to maintain remission, in line with observational studies in established RA and from the PRESERVE trial, where termination of etanercept in stable LDA resulted in a lower likelihood of maintaining LDA than continuing etanercept. However, unlike in CERTAIN, comparisons between patients receiving etanercept and those who only continued prior non-biologic DMARD treatment could not be ascertained in PRESERVE due to the open-label nature of the run-in period that only included etanercept therapy and no placebo control. In the CERTAIN study, somewhat more frequent flares were seen after anti-TNF withdrawal than in the PRESERVE study; this is likely a consequence of the requirement of achieving the clinical target for at least 6 months before withdrawal in the PRESERVE study compared with at least 4 weeks in the CERTAIN study; moreover, the treatment target was more stringent in the CERTAIN study (CDAI remission vs DAS28 LDA). In contrast to CERTAIN and PRESERVE studies, the Optimal Protocol for Treatment Initiation With Methotrexate and Adalimumab Combination Therapy in Patients With Early Rheumatoid Arthritis (OPTIMA) study assessed early RA patients and revealed that most of them were able to maintain DAS28 LDA upon stopping adalimumab and continuing MTX; only a relatively small number of patients would have benefited from continuing or reinstituting adalimumab. This difference suggests that, contrasting with early disease, biological therapy should not be stopped in established disease once an acceptable disease activity state has been attained, in agreement with observational studies.

Alternatively, a longer remission state may be necessary prior to stopping biological therapy.

In line with observational studies on retreatment with biologics and contrasting with DMARD retreatment, among patients receiving CZP retreatment after flaring to MDA/HDA, almost half (4/10) of the prior CZP-treated patients re-achieved remission, and the remaining 6 LDA; thus, all these patients showed response to retreatment. Such retreatment was not assessed in PRESERVE or OPTIMA studies.

There are several limitations to this study. First, only a small number of patients were included in the follow-up since fewer patients than expected achieved remission, presumably a consequence of long-standing disease and stringent remission criteria. At the time of study design, there were no prior data available from patients with MDA or LDA and so the actual proportions of patients achieving sustained remission indicate that this trial was not adequately powered, which is a limitation of the study; however, despite this underpowering, the differences between the treatment arms were significant. Also, in a recent analysis from an observational prospective RA database, patient’s global assessment of disease activity was often the limiting factor to reach remission; this may also have contributed to the low CDAI remission rates in this study of patients with long-standing RA, and, indeed, the greatest mean contribution to the CDAI in patients not reaching remission at week 24 on certolizumab pegol came from the patient’s global assessment (data not shown). Second, retreatment upon flaring was not performed in a placebo-controlled manner but as an open-label exploratory analysis; nevertheless, it is unlikely that we observed a placebo effect upon retreatment since disease activity increased also in the placebo arm and patients remained masked to the initial double-blind period. Third, we did not assess dose reduction or interval increase once patients achieved remission, a strategy reported effective in maintaining LDA in the PRESERVE trial.

The results presented here reveal that CZP addition to non-biologic DMARDs in patients with long-standing, mostly MDA associated with increased remission and LDA rates, prevention of worsening and improvements in physical function, quality of life, work productivity and daily activities. Remission was lost upon discontinuation of CZP treatment, although response was regained by reinstitution of CZP. Taken alongside the level of overall impairment in persistent MDA and the low likelihood of these patients achieving LDA/remission with DMARD treatment alone, the data suggest that RA patients with LDA/MDA are a relevant population to treat with TNF inhibitors.

Author affiliations
1Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, and 2nd Department of Medicine, Hietzing Hospital, Vienna, Austria
2Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, UK
3NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK
4Institute of Rheumatology and Allife Sciences, Catholic University of the Sacred Heart, Rome, Italy
5University of Medical Sciences, Poznan, Poland
6Department of Rheumatology, DHU UZB, INSERM U-938, Pierre & Marie Curie University Paris 06, Saint-Antoine hospital, AP-HP, Paris, France
7UCB Pharma, Brussels, Belgium
8UCB Pharma, Raleigh, North Carolina, USA
9BBennett Consulting, Marietta, USA
10CIRI/Division of Rheumatology and Fraunhofer TMM, Goethe-University, Frankfurt am Main, Germany

Acknowledgements The authors acknowledge Mr Matladi Ndlovu, PhD, UCB Pharma, Brussels, Belgium, for publication management and Costello Medical Consulting for editorial and administrative support.

Contributors JJS has received grants from and provided expert advice to UCB Pharma. PE has received grants from and is a consultant for UCB Pharma. GFF has received speaking fees from UCB Pharma. WS, FB and HB are consultants for UCB Pharma. ORD is a shareholder and employee of UCB Pharma. WK and OP are employees of UCB Pharma. BB is a former employee of UCB Pharma.

Funding This study was funded by UCB Pharma.

Competing interests JJS has received grants from and provided expert advice to UCB Pharma. PE has received grants and consultancy fees from UCB Pharma, Pfizer, Merck, Abbott, Roche and BMS. GF has received speaking fees from UCB Pharma.


31 Sokka T, Pincus T. Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or American College of Rheumatology criteria for remission. J Rheumatol 2003;30:1138–46.


SUPPLEMENTARY INFORMATION

METHODS

Exclusion Criteria

Exclusion criteria included a history of a non-inflammatory type of joint disease that may interfere with evaluation of the study drug on RA, chronic infections or recent serious infections, concurrent malignancy or demyelinating disorder. Patients with active or latent tuberculosis, or a positive purified protein derivative (PPD) test, were also excluded. In addition, patients were excluded if they had previously received any biologic therapy for RA.

Study Design

During the OLE study, patients received CZP 400 mg at Weeks 0, 2 and 4, unless they had received this loading dose following a flare between Weeks 24 and 50, and CZP 200 mg Q2W thereafter (Figure 1A).

Efficacy evaluations

The exploratory objective of impact of patients’ disease activity on work productivity and regular activities was investigated using the WPAI-RA questionnaire[1] and was measured at Weeks 0, 24 and 52. This assessed the impact of RA on 4 dimensions: work absenteeism (sick leave), work presenteeism (work impairment whilst working), overall work impairment and daily activity impairment over the 7 days prior to the respective study visit. WPAI-RA results are presented as observed data on which no statistical analyses were conducted.

Safety evaluations

Safety analysis comprised of physical examinations (including monitoring for any signs or symptoms of tuberculosis), measurement of vital signs and clinical laboratory values, and assessment of all AEs, serious AEs (SAEs), injection-site reactions and serious infections.
RESULTS

Safety

The frequency of injection site reactions was 3.1% and 2.0% in CZP and placebo groups, respectively. There was only one case of injection site pain (1.0%), in the placebo group. In the 27 patients who continued in the follow-up period, the most frequently reported AEs included infections and infestations, gastrointestinal disorders and nervous system disorders (Table S2). The only SAE was one event of cerebrovascular accident (in the prior CZP group).

REFERENCES

Table S1. ACR core components and patient-reported outcomes at Baseline and Week 24 (LOCF).

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>Week 24</th>
<th>Change from Baseline</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo</td>
<td>CZP</td>
<td>Placebo</td>
</tr>
<tr>
<td></td>
<td>(n=98)</td>
<td>(n=96)</td>
<td>(n=98)</td>
</tr>
<tr>
<td><strong>ACR Core Components</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TJC</td>
<td>3.9 (1.6)</td>
<td>3.7 (1.5)</td>
<td>5.7 (5.4)</td>
</tr>
<tr>
<td>SJC</td>
<td>3.2 (1.3)</td>
<td>3.4 (1.5)</td>
<td>4.1 (3.6)</td>
</tr>
<tr>
<td>Patient's global assessment of pain (VAS)</td>
<td>36.8 (19.1)</td>
<td>36.9 (20.8)</td>
<td>37.1 (26.3)</td>
</tr>
<tr>
<td>Patient's global assessment of disease activity (VAS)</td>
<td>35.6 (16.7)</td>
<td>36.7 (18.5)</td>
<td>38.3 (25.0)</td>
</tr>
<tr>
<td>Physician's global assessment of disease activity (VAS)</td>
<td>27.2 (10.7)</td>
<td>26.9 (10.5)</td>
<td>30.4 (20.1)</td>
</tr>
<tr>
<td>HAQ-DI</td>
<td>1.04 (0.60)</td>
<td>1.11 (0.62)</td>
<td>1.00 (0.68)</td>
</tr>
<tr>
<td>CRP geometric mean (CV) – ratio to Baseline</td>
<td>8.6 (116.6)</td>
<td>7.2 (114.2)</td>
<td>8.4 (125.0)</td>
</tr>
<tr>
<td>ESR geometric mean (CV) – ratio to Baseline</td>
<td>31.5 (38.6)</td>
<td>32.1 (40.1)</td>
<td>22.4 (77.5)</td>
</tr>
<tr>
<td><strong>Other Patient Reported Outcomes</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FAS</td>
<td>4.3 (2.0)</td>
<td>4.9 (2.4)</td>
<td>4.3 (2.4)</td>
</tr>
<tr>
<td>SF-36†</td>
<td>36.9 (7.2)</td>
<td>35.2 (7.2)</td>
<td>38.0 (7.8)</td>
</tr>
<tr>
<td></td>
<td>44.3 (11.2)</td>
<td>42.1 (10.2)</td>
<td>44.7 (11.3)</td>
</tr>
</tbody>
</table>

*p≤0.05 (CZP – placebo LS mean difference in change from Baseline); **p≤0.01 (CZP – placebo LS mean difference in change from Baseline); ***p≤0.001 (CZP – placebo LS mean difference in change from Baseline). †Values are reported for the observed set, with no imputation method. There were no statistical comparisons for TJC, SJC, CRP and ESR. HAQ-DI, Health assessment questionnaire–disability index; TJC, Tender joint count; SJC, Swollen joint count; VAS, Visual analog scale; CV, Coefficient of variation; FAS, Fatigue assessment scale; SF-36, Short form health survey with 36 questions; PCS, Physical component summary; MCS, Mental component summary.
**Table S2:** Treatment-emergent adverse events in the safety population during the open-label follow-up period.

<table>
<thead>
<tr>
<th><strong>Open-label follow-up period</strong></th>
<th>Prior placebo (n=7)</th>
<th>Prior CZP (n=20)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Any AE, n (%)</strong></td>
<td>0</td>
<td>7 (35.0%)</td>
</tr>
<tr>
<td><strong>Drug related, n (%)</strong></td>
<td>0</td>
<td>1 (5.0%)</td>
</tr>
<tr>
<td><strong>Infections and infestations</strong></td>
<td>0</td>
<td>4 (20.0%)</td>
</tr>
<tr>
<td><strong>Serious AEs, n (%)</strong></td>
<td>0</td>
<td>1 (5.0%)</td>
</tr>
<tr>
<td><strong>Serious infections, n (%)</strong></td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Malignancies</strong></td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>AE leading to death, n (%)</strong></td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>AE leading to withdrawal</strong></td>
<td>0</td>
<td>1 (5.0%)</td>
</tr>
</tbody>
</table>

**Most common AE**

<table>
<thead>
<tr>
<th>System order class</th>
<th>Preferred term</th>
<th>Prior placebo (n=7)</th>
<th>Prior CZP (n=20)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gastrointestinal disorders</strong></td>
<td>Nausea</td>
<td>0</td>
<td>2 (10.0%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>General disorders and administration site conditions</strong></td>
<td>Influenza-like illness</td>
<td>0</td>
<td>1 (5.0%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Infections and infestations</strong></td>
<td>Bronchitis</td>
<td>0</td>
<td>2 (10.0%)</td>
</tr>
<tr>
<td></td>
<td>Laryngitis</td>
<td>0</td>
<td>1 (5.0%)</td>
</tr>
<tr>
<td></td>
<td>Rhinitis</td>
<td>0</td>
<td>1 (5.0%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Nervous system disorders</strong></td>
<td>Cerebrovascular accident</td>
<td>0</td>
<td>1 (5.0%)</td>
</tr>
<tr>
<td></td>
<td>Syncope vasovagal</td>
<td>0</td>
<td>1 (5.0%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Psychiatric disorders</strong></td>
<td>Depression</td>
<td>0</td>
<td>1 (5.0%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Respiratory, thoracic and mediastinal disorders</strong></td>
<td>Cough</td>
<td>0</td>
<td>1 (5.0%)</td>
</tr>
<tr>
<td></td>
<td>Rhinorrhoea</td>
<td>0</td>
<td>1 (5.0%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Skin and subcutaneous tissue disorders</strong></td>
<td>Hyperhidrosis</td>
<td>0</td>
<td>1 (5.0%)</td>
</tr>
</tbody>
</table>

Results are shown as n (%) of patients. *Temporary or permanent discontinuation of the drug.

**Treatment-emergent adverse events occurring in >3% of the safety population in the specified period (in either CZP or placebo group). AE, Adverse event.**
SUPPLEMENTARY FIGURE TITLES AND LEGENDS

**Figure S1.** (A) Mean DAS28(ESR) scores up to Week 24 (LOCF); (B) DAS28(ESR) disease state at Baseline, Week 12 and Week 24 (LOCF); (C) Mean SDAI scores up to Week 24 (LOCF); (D) SDAI disease state at Baseline, Week 12 and Week 24 (LOCF).

**Figure S2.** Effect of CZP on work productivity and daily activities. (A) Absenteeism (% work time missed due to RA); (B) Presenteeism (% impairment while working due to RA); (C) Overall work impairment due to RA (%); (D) Daily activity impairment due to RA (%) (ITT population, observed data).

**Figure S3.** Kaplan-Meier curve for loss of CDAI remission (CDAI score >2.8 at 2 consecutive visits) after Week 24 (W24 Remitter Set, n=24).
A) Work time missed due to RA (%)

B) Impairment while working due to RA (%)

C) Overall work impairment due to RA (%)

D) Daily activity impairment due to RA (%)

* Based on employed patients only.

180x228mm (300 x 300 DPI)
Patients who completed the Week 52 visit or withdrew after Week 24 visit without losing remission were censored in analysis at the time of completion or withdrawal.